[Nicotinic acid and derivatives for therapy of hyperlipoproteinemia].
Nicotinic acid and derivatives are effective in numerous forms of hyperlipoproteinemia. Its primary mode of action is to inhibit lipolysis in adipose tissue and to prevent the utilization of free fatty acids for TG-rich lipoprotein synthesis in the liver. Consequently, it decreases the plasma lipoproteins which are considered to be atherogenic--VLDL, LDL and Lp(a), while it increases the antiatherogenic lipoprotein--HDL. A gradual administration of nicotinic acid or derivatives is useful to reduce the side effects such as flushing and itching. In the secondary prevention trials, nicotinic acid therapy with other hypolipidemic drugs asserted protective effects on the development/progression of cardiovascular disease.
Ishikawa
T
T
First Department of Medicine, Defense Medical College.
D000273:Adipose Tissue / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D008066:Lipolysis / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism; D009539:Nicotinic Acids / Q000494:pharmacology / Q000627:therapeutic use*
D005230:Fatty Acids, Nonesterified; D008074:Lipoproteins; D009539:Nicotinic Acids